
UB786
TargetsTAAR1 and 5-HT(2C)R
IndicationsSchizophrenia; Alzheimer's disease psychosis
ClinicalCN - II
TherapeuticsPsychiatry; Neurology
ModalitiesSmall Molecule
Exclusive Summary
- Seize the imminent patent cliff window through an out-licensing model, empowering overseas clients to achieve first-to-file registration or Day-1 commercial launch.
- Target a massive global market addressing millions of patients, providing an indispensable, authoritative guideline-recommended first-line standard-of-care therapy.
- Deliver robust tender and pricing competitiveness leveraging international quality certifications and the extraordinary cost efficiency of vertically integrated API-to-FDF manufacturing.
Asset Materials

How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →